

Haematologica
HAEMATOL/2016/163030
Version 3

Inhibition of monocarboxylate transporter 1 by AZD3965 as a novel
therapeutic approach for the treatment of diffuse large B-cell lymphoma
and Burkitt lymphoma

Richard A. Noble, Natalie Bell, Helen Blair, Arti Sikka, Huw Thomas,
Nicole Phillips, Sirintra Nakjang, Satomi Miwa, Rachel Crossland, Vikki
Rand, Despina Televantou, Anna Long, Hector C. Keun, Chris M.
Bacon, Simon Bomken, Susan E. Critchlow, and Stephen R. Wedge

Disclosures: Stephen R. Wedge and Susan E. Critchlow are former and current employees of AstraZeneca respectively and current share-holders. Richard A. Noble undertook an AstraZeneca and BBSRC-funded CASE Ph.D. studentship during the course of this work. No conflicts of interest were disclosed by other authors.

Contributions: Study design: SRW, RAN and SEC. Development of methodology: SRW, RAN, CMB, NB, SB, HCK and SM. Acquisition of data: RAN, NB, HB, AS, HT, NP, AL, DT and CMB. Material support: RC and VR. Analysis and interpretation of data: SRW, RAN, NB, HB, AS, SN, HCK, CMB and SB. Writing and review of the manuscript: SRW, RAN, HCK, CMB, SB and SEC.